# Wilex

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wilex

- Industry: Healthcare
- Headquarters: Munich, Germany
- Website: www.wilex.de
- Total disclosed funding: $39M
- Latest round: Series C (May 10, 2005)
- Investors on record: 7

## About

Wilex AG is a biotechnology company focused on developing innovative therapies for the treatment of cancer using its proprietary Antibody-Drug Conjugate (ADC) technology. The firm is dedicated to targeting malignant cells with high precision.Wilex AG specializes in the development of Antibody-Drug Conjugates (ADCs) aimed at addressing various cancer types. Founded in 1997 in Munich, Germany, the company has undergone strategic pivots to refine its focus on ADC technology. The CEO, Jan Schmidt-Brand, leads the company in its initiatives. Wilex AG has raised a total of EUR 27.10 mn across several funding rounds, with the latest being a Grant of EUR 2.60 mn from the Federal Ministry of Education and Research in November 2006. The firm has completed 6 deals since its inception, showing a consistent interest in advancing its clinical and therapeutic approaches.Wilex AG develops Antibody-Drug Conjugates (ADCs) that target and destroy cancer cells with high specificity, utilizing their proprietary ATAC technology. This technology leverages Amanitin, a potent substance derived from mushrooms, to overcome drug resistance in tumors, providing new treatment options for patients who do not respond to standard therapies. Their offerings cater to the needs of healthcare providers and oncology specialists in the European and North American markets, focusing on enhancing patient outcomes through their advanced therapeutic solutions.In the most recent fiscal year, Wilex AG reported a revenue of EUR 10,643,788.60. Despite this revenue, the company experienced an EBITDA of EUR -21,949,881.80, indicating its ongoing investment in research and development as it advances its product pipeline.Looking ahead, Wilex AG plans to expand its product lineup with new ADC therapies designed to target additional cancer types, although specific product release dates have not been disclosed. The company is also focused on entering new markets, particularly in regions across Europe and North America, intending to broaden its reach by 2025. The funds raised in the latest Grant will support these growth initiatives, allowing the company to further enhance its research capabilities and market presence.

## Funding rounds

- Series C, May 10, 2005, $39M — Apax Partners, TVM Capital Life Science, Excalibur Fund Managers, Quintiles Transnational, KI Management, Earlybird, Quest Management

## Investors

- Apax Partners (https://capitalatlas.ai/funds/apax-partners) — Series C
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series C
- Excalibur Fund Managers (https://capitalatlas.ai/funds/excalibur-fund-managers) — Series C
- Quintiles Transnational — Series C
- KI Management (https://capitalatlas.ai/funds/ki-management) — Series C
- Earlybird (https://capitalatlas.ai/funds/earlybird) — Series C
- Quest Management (https://capitalatlas.ai/funds/quest-management) — Series C